Plocamium Global Insights

Gilead Breaks Decades-Long Drought With First Hepatitis Delta Drug, Now Faces Hunt For 60,000 Undiagnosed Patients

10 min · 23. maj 2026
episode Gilead Breaks Decades-Long Drought With First Hepatitis Delta Drug, Now Faces Hunt For 60,000 Undiagnosed Patients cover

Beskrivelse

Gilead Sciences secured a rare commercial advantage on May 22, 2026, when the FDA approved Hepcludex (bulevirtide-gmod) as the first treatment for chronic hepatitis delta virus infection in adults—ending a decades-long therapeutic drought for a disease that accelerates liver failure faster than hepa

Kommentarer

0

Vær den første til at kommentere

Tilmeld dig nu og bliv en del af Plocamium Global Insights-fællesskabet!

Kom i gang

1 måned kun 9 kr.

Derefter 99 kr. / måned · Opsig når som helst.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

Alle episoder

429 episoder